Switch to:
Also traded in: Denmark, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 73.60
OTCPK:NONOF's Cash-to-Debt is ranked lower than
55% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. OTCPK:NONOF: 73.60 )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:NONOF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: 4.85 Max: 90.39
Current: 73.6
0.29
90.39
Equity-to-Asset 0.48
OTCPK:NONOF's Equity-to-Asset is ranked lower than
67% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OTCPK:NONOF: 0.48 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:NONOF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.62 Max: 0.73
Current: 0.48
0.42
0.73
Debt-to-Equity 0.01
OTCPK:NONOF's Debt-to-Equity is ranked higher than
84% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. OTCPK:NONOF: 0.01 )
Ranked among companies with meaningful Debt-to-Equity only.
OTCPK:NONOF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.05 Max: 0.54
Current: 0.01
0.01
0.54
Debt-to-EBITDA 0.01
OTCPK:NONOF's Debt-to-EBITDA is ranked higher than
97% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. OTCPK:NONOF: 0.01 )
Ranked among companies with meaningful Debt-to-EBITDA only.
OTCPK:NONOF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0  Med: 0.03 Max: 0.15
Current: 0.01
0
0.15
Interest Coverage 33.06
OTCPK:NONOF's Interest Coverage is ranked lower than
78% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OTCPK:NONOF: 33.06 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:NONOF' s Interest Coverage Range Over the Past 10 Years
Min: 9.18  Med: 279.29 Max: 884.41
Current: 33.06
9.18
884.41
Piotroski F-Score: 7
Altman Z-Score: 13.13
Beneish M-Score: -2.77
WACC vs ROIC
9.67%
151.62%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 44.25
OTCPK:NONOF's Operating Margin % is ranked higher than
96% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. OTCPK:NONOF: 44.25 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:NONOF' s Operating Margin % Range Over the Past 10 Years
Min: 21.38  Med: 35.7 Max: 45.81
Current: 44.25
21.38
45.81
Net Margin % 34.05
OTCPK:NONOF's Net Margin % is ranked higher than
95% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. OTCPK:NONOF: 34.05 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:NONOF' s Net Margin % Range Over the Past 10 Years
Min: 20.38  Med: 26.62 Max: 34.05
Current: 34.05
20.38
34.05
ROE % 86.77
OTCPK:NONOF's ROE % is ranked higher than
99% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. OTCPK:NONOF: 86.77 )
Ranked among companies with meaningful ROE % only.
OTCPK:NONOF' s ROE % Range Over the Past 10 Years
Min: 27.38  Med: 50.43 Max: 86.77
Current: 86.77
27.38
86.77
ROA % 40.62
OTCPK:NONOF's ROA % is ranked higher than
99% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. OTCPK:NONOF: 40.62 )
Ranked among companies with meaningful ROA % only.
OTCPK:NONOF' s ROA % Range Over the Past 10 Years
Min: 18.46  Med: 30 Max: 41.29
Current: 40.62
18.46
41.29
ROC (Joel Greenblatt) % 163.63
OTCPK:NONOF's ROC (Joel Greenblatt) % is ranked higher than
96% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. OTCPK:NONOF: 163.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:NONOF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 43  Med: 107.33 Max: 178.92
Current: 163.63
43
178.92
3-Year Revenue Growth Rate 12.40
OTCPK:NONOF's 3-Year Revenue Growth Rate is ranked higher than
64% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. OTCPK:NONOF: 12.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OTCPK:NONOF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -46.3  Med: 12.4 Max: 127.9
Current: 12.4
-46.3
127.9
3-Year EBITDA Growth Rate 15.30
OTCPK:NONOF's 3-Year EBITDA Growth Rate is ranked higher than
65% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. OTCPK:NONOF: 15.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OTCPK:NONOF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -44.4  Med: 14.7 Max: 130.3
Current: 15.3
-44.4
130.3
3-Year EPS without NRI Growth Rate 17.00
OTCPK:NONOF's 3-Year EPS without NRI Growth Rate is ranked higher than
71% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. OTCPK:NONOF: 17.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OTCPK:NONOF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 1.3  Med: 16.7 Max: 36.9
Current: 17
1.3
36.9
GuruFocus has detected 4 Warning Signs with Novo Nordisk A/S OTCPK:NONOF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:NONOF's 30-Y Financials

Financials (Next Earnings Date: 2018-02-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with OTCPK:NONOF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2836
Compare:NAS:AMGN, NAS:GILD, NAS:CELG, NAS:BIIB, ASX:CSL, NAS:REGN, LSE:SHP, NAS:VRTX, XSWX:ATLN, NAS:ALXN, NAS:INCY, XKRX:207940, XKRX:068270, XMCE:GRF.P, OCSE:NZYM B, SZSE:002252, NAS:BMRN, XBRU:UCB, OCSE:GEN, NAS:ALNY » details
Traded in other countries:NOVO B.Denmark, NOVA.Germany, NVON.Mexico, NOVOB.Switzerland, 0QIU.UK, NVO.USA,
Headquarter Location:Denmark
Novo Nordisk A/S is a healthcare company. It is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The company's business segments include, diabetes and obesity care, and biopharmaceuticals.

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, as well as oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 20% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Top Ranked Articles about Novo Nordisk A/S

"Diabetes 360" Survey Shows Patients Want More Than Medicine, Need Emotional Support
Novo Nordisk Gets FDA Panel's OK for Diabetes Drug Group votes unanimously to recommend approval of drug to compete with Eli Lilly
Novo Nordisk A/S (NYSE:NVO) just announced that an FDA advisory panel has voted in favor of the approval of one of its lead diabetes assets and the company is picking up some favorable attention in the space on the back of the news. Read more...
Novo Nordisk receives positive 16-0 vote from FDA Advisory Committee in favor of approval for semaglutide
Novo Nordisk Receives FDA Approval for Fiasp®, a New Fast-Acting Mealtime Insulin
Working Mother names Novo Nordisk one of its "100 Best Companies"
Novo Nordisk announces conclusion of U.S. federal investigation of marketing practices
Victoza® (liraglutide) is approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of three major adverse cardiovascular events
3 Companies Aiming to Significantly Reduce Diabetes Treatment Costs Diabetes accounts for nearly 10% of US health care spending
Total U.S. health care spending in 2015 was an astronomical $3.2 trillion. That is 16% of the entire national debt. As much as we blame the prices of new drugs for this gargantuan sum, one of the biggest chunks of it comes from diabetes, a disease whose treatment has not changed all that much since 1922. According to the American Diabetes Association, diabetes accounts for $322 billion in total U.S. health care spending as of 2016. Read more...
Score Big Returns With Dividend Growth Companies Backtesting identifies winning investing strategies for 2017
Among U.S. companies, high dividend yield companies like Cisco Systems Inc. (NASDAQ:CSCO), Infosys Ltd. (NYSE:INFY), Novo Nordisk A/S (NYSE:NVO), Strum Ruger & Co. Inc. (NYSE:RGR) and Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE:TSM) generated high portfolio returns during the backtesting period from January 2006 to January 2017. Read more...
Novo Nordisk and Glooko advance their digital health collaboration with launch of unique integrated app for improved diabetes management

Ratios

vs
industry
vs
history
PE Ratio 21.19
NONOF's PE Ratio is ranked higher than
68% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. NONOF: 21.19 )
Ranked among companies with meaningful PE Ratio only.
NONOF' s PE Ratio Range Over the Past 10 Years
Min: 12.13  Med: 23.34 Max: 34.41
Current: 21.19
12.13
34.41
Forward PE Ratio 19.80
NONOF's Forward PE Ratio is ranked higher than
65% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 24.21 vs. NONOF: 19.80 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 21.19
NONOF's PE Ratio without NRI is ranked higher than
69% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 29.70 vs. NONOF: 21.19 )
Ranked among companies with meaningful PE Ratio without NRI only.
NONOF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.13  Med: 23.35 Max: 34.41
Current: 21.19
12.13
34.41
Price-to-Owner-Earnings 23.24
NONOF's Price-to-Owner-Earnings is ranked higher than
67% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 38.46 vs. NONOF: 23.24 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NONOF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 15.62  Med: 26.42 Max: 60.24
Current: 23.24
15.62
60.24
PB Ratio 17.51
NONOF's PB Ratio is ranked lower than
89% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. NONOF: 17.51 )
Ranked among companies with meaningful PB Ratio only.
NONOF' s PB Ratio Range Over the Past 10 Years
Min: 3.68  Med: 11.86 Max: 31.9
Current: 17.51
3.68
31.9
PS Ratio 7.23
NONOF's PS Ratio is ranked higher than
64% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. NONOF: 7.23 )
Ranked among companies with meaningful PS Ratio only.
NONOF' s PS Ratio Range Over the Past 10 Years
Min: 2.81  Med: 6.01 Max: 10.99
Current: 7.23
2.81
10.99
Price-to-Free-Cash-Flow 21.46
NONOF's Price-to-Free-Cash-Flow is ranked higher than
69% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. NONOF: 21.46 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NONOF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.75  Med: 24.24 Max: 46.97
Current: 21.46
12.75
46.97
Price-to-Operating-Cash-Flow 17.67
NONOF's Price-to-Operating-Cash-Flow is ranked higher than
69% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. NONOF: 17.67 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NONOF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.65  Med: 19.83 Max: 32.48
Current: 17.67
10.65
32.48
EV-to-EBIT 15.54
NONOF's EV-to-EBIT is ranked higher than
65% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. NONOF: 15.54 )
Ranked among companies with meaningful EV-to-EBIT only.
NONOF' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.1  Med: 16.7 Max: 25.7
Current: 15.54
10.1
25.7
EV-to-EBITDA 14.56
NONOF's EV-to-EBITDA is ranked higher than
65% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. NONOF: 14.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
NONOF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.6  Med: 16 Max: 23.6
Current: 14.56
9.6
23.6
EV-to-Revenue 6.94
NONOF's EV-to-Revenue is ranked higher than
66% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. NONOF: 6.94 )
Ranked among companies with meaningful EV-to-Revenue only.
NONOF' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.7  Med: 5.8 Max: 10.9
Current: 6.94
2.7
10.9
PEG Ratio 1.23
NONOF's PEG Ratio is ranked higher than
64% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.09 vs. NONOF: 1.23 )
Ranked among companies with meaningful PEG Ratio only.
NONOF' s PEG Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.13 Max: 5.14
Current: 1.23
0.7
5.14
Shiller PE Ratio 35.84
NONOF's Shiller PE Ratio is ranked higher than
69% of the 70 Companies
in the Global Biotechnology industry.

( Industry Median: 41.36 vs. NONOF: 35.84 )
Ranked among companies with meaningful Shiller PE Ratio only.
NONOF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 24.74  Med: 42.67 Max: 67.81
Current: 35.84
24.74
67.81
Current Ratio 1.27
NONOF's Current Ratio is ranked lower than
83% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. NONOF: 1.27 )
Ranked among companies with meaningful Current Ratio only.
NONOF' s Current Ratio Range Over the Past 10 Years
Min: 1.04  Med: 1.96 Max: 3.09
Current: 1.27
1.04
3.09
Quick Ratio 0.93
NONOF's Quick Ratio is ranked lower than
85% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. NONOF: 0.93 )
Ranked among companies with meaningful Quick Ratio only.
NONOF' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.32 Max: 2.6
Current: 0.93
0.74
2.6
Days Inventory 302.20
NONOF's Days Inventory is ranked lower than
84% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. NONOF: 302.20 )
Ranked among companies with meaningful Days Inventory only.
NONOF' s Days Inventory Range Over the Past 10 Years
Min: 246.45  Med: 282.52 Max: 343.56
Current: 302.2
246.45
343.56
Days Sales Outstanding 55.42
NONOF's Days Sales Outstanding is ranked higher than
60% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. NONOF: 55.42 )
Ranked among companies with meaningful Days Sales Outstanding only.
NONOF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.09  Med: 51.9 Max: 66.07
Current: 55.42
45.09
66.07
Days Payable 92.63
NONOF's Days Payable is ranked higher than
68% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. NONOF: 92.63 )
Ranked among companies with meaningful Days Payable only.
NONOF' s Days Payable Range Over the Past 10 Years
Min: 72.54  Med: 100.02 Max: 127.69
Current: 92.63
72.54
127.69

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.31
NONOF's Dividend Yield % is ranked higher than
85% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 1.24 vs. NONOF: 1.31 )
Ranked among companies with meaningful Dividend Yield % only.
NONOF' s Dividend Yield % Range Over the Past 10 Years
Min: 0.93  Med: 1.6 Max: 4.17
Current: 1.31
0.93
4.17
Dividend Payout Ratio 0.30
NONOF's Dividend Payout Ratio is ranked lower than
77% of the 133 Companies
in the Global Biotechnology industry.

( Industry Median: 0.39 vs. NONOF: 0.30 )
Ranked among companies with meaningful Dividend Payout Ratio only.
NONOF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.26  Med: 0.35 Max: 0.63
Current: 0.3
0.26
0.63
3-Year Dividend Growth Rate 37.70
NONOF's 3-Year Dividend Growth Rate is ranked higher than
85% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. NONOF: 37.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
NONOF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -2.1  Med: 18.6 Max: 37.7
Current: 37.7
-2.1
37.7
Forward Dividend Yield % 2.19
NONOF's Forward Dividend Yield % is ranked higher than
84% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 1.25 vs. NONOF: 2.19 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 5.23
NONOF's 5-Year Yield-on-Cost % is ranked higher than
93% of the 305 Companies
in the Global Biotechnology industry.

( Industry Median: 1.61 vs. NONOF: 5.23 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NONOF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.71  Med: 6.39 Max: 16.65
Current: 5.23
3.71
16.65
3-Year Average Share Buyback Ratio 1.80
NONOF's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. NONOF: 1.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NONOF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.6  Med: 0.7 Max: 8
Current: 1.8
-13.6
8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 134.74
NONOF's Price-to-Net-Current-Asset-Value is ranked lower than
96% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. NONOF: 134.74 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NONOF' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 11.79  Med: 25.16 Max: 696.47
Current: 134.74
11.79
696.47
Price-to-Tangible-Book 18.55
NONOF's Price-to-Tangible-Book is ranked lower than
86% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. NONOF: 18.55 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NONOF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.14  Med: 7.96 Max: 31.52
Current: 18.55
3.14
31.52
Price-to-Intrinsic-Value-Projected-FCF 1.74
NONOF's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
75% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.43 vs. NONOF: 1.74 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NONOF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.36  Med: 2.31 Max: 7.38
Current: 1.74
1.36
7.38
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.74
NONOF's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
93% of the 27 Companies
in the Global Biotechnology industry.

( Industry Median: 1.85 vs. NONOF: 0.74 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
NONOF' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.48  Med: 0.9 Max: 1.14
Current: 0.74
0.48
1.14
Price-to-Median-PS-Value 1.20
NONOF's Price-to-Median-PS-Value is ranked lower than
59% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. NONOF: 1.20 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NONOF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 0.82 Max: 1.73
Current: 1.2
0.13
1.73
Price-to-Peter-Lynch-Fair-Value 1.19
NONOF's Price-to-Peter-Lynch-Fair-Value is ranked higher than
77% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 1.79 vs. NONOF: 1.19 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
NONOF' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.19  Med: 1.02 Max: 3.78
Current: 1.19
0.19
3.78
Price-to-Graham-Number 4.18
NONOF's Price-to-Graham-Number is ranked lower than
64% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 2.69 vs. NONOF: 4.18 )
Ranked among companies with meaningful Price-to-Graham-Number only.
NONOF' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.58  Med: 2.87 Max: 6.75
Current: 4.18
1.58
6.75
Earnings Yield (Greenblatt) % 6.44
NONOF's Earnings Yield (Greenblatt) % is ranked higher than
91% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. NONOF: 6.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NONOF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.9  Med: 6 Max: 9.9
Current: 6.44
3.9
9.9
Forward Rate of Return (Yacktman) % 21.31
NONOF's Forward Rate of Return (Yacktman) % is ranked higher than
69% of the 132 Companies
in the Global Biotechnology industry.

( Industry Median: 13.13 vs. NONOF: 21.31 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NONOF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.5  Med: 22.9 Max: 33.5
Current: 21.31
7.5
33.5

More Statistics

Revenue (TTM) (Mil) $16,870.97
EPS (TTM) $ 2.31
Beta0.76
Short Percentage of Float0.00%
52-Week Range $31.07 - 51.20
Shares Outstanding (Mil)2,450.58

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 17,591 18,556 19,354
EPS ($) 2.42 2.59 2.76
EPS without NRI ($) 2.42 2.59 2.76
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.49%
Dividends per Share ($) 1.38 1.48 1.81

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}